Objectives The objective of this research was to elucidate the current practice of managing parenteral nutrition during intravenous multivitamin shortages in Switzerland with a focus on the last segment of the supply chain from the hospital to the HPN patient. Methods We conducted 17 structured interviews based on but also extended from the 2018 ESPEN survey with experts involved in the hospital parenteral nutrition supply (healthcare professionals, a public servant, and industry representatives) and included patients on home parenteral nutrition. Results Awareness and experience with intravenous multivitamin shortages were high among professionals but not in patients. Overall, eight (47%) of the professionals experienced long-lasting shortages (>90 days). Mentioned reasons for shortages were packaging material and transport issues, problems in the procurement of raw materials, lack of personnel due to the COVID-19 pandemic, changed industrial manufacturing prioritizing, e.g. for mRNA vaccines, the 2021 Suez Canal blockade, low market price, and national authorization withdrawal. Conclusions The considerations set out in this paper make it clear that a combination of short-term measures is needed. Managing intravenous multivitamin shortages is a common task and European guidelines including prioritization of patients relying on intravenous multivitamins are warranted as the home parenteral nutrition care is complex affecting highly vulnerable patients.  Kulcsszavak: deficiency, drug shortage, multivitamin, (home) parenteral nutrition, management guidance